Quanticate Names Daniel Chapple Vice President Global Business Development & Marketing

Quanticate has announced that it has named Dr. Daniel Chapple as the company's Vice President of Business Development and Marketing.

Reporting to Quanticate's Chairman and Chief Executive Officer David Underwood, Chapple will work within Quanticate's offices in Boston, MA and the UK.

Drawing from Chapple's recent position as General Manager at Cognizant's Life Sciences BPO practice, Quanticate will leverage his business development leadership and extensive knowledge of the clinical CRO space, including full service CROs, specialist BPOs and solutions expertise in the pharmaceutical, biotechnology and medical device sectors.

"Daniel's customer-focused orientation, self-awareness, and strong business acumen skills make him a good fit as part of our executive management team," said Underwood.

Underwood continued, "This is an exciting time at Quanticate as we are growing our operations in the US and India to support our teams already in place in the UK, Poland and South Africa. Daniel will help to streamline our approach to working across these regions to support our clients at the functional and task level due to his strong background."

Through the use of technology coupled with highly skilled statisticians, programmers, data managers, medical writers and pharmacovigilance experts, Chapple will further focus the Centralized Clinical Data Sciences solution which will help leverage the data required to secure approvals and market new products.

This approach supports the growing requirement of the life sciences industry to reduce timelines, minimize regulatory delays and reduce costs associated with the drug development process.

"Our team has incredible amounts of experience and many of our staff are recognized experts in the industry," said Chapple.

Chapple continued, "As the expectations of regulatory bodies continue to rise, pharmaceutical companies are under intense pressure to optimize costs through increasing productivity, lowering internal costs and implementing strategic partnerships. It is not just about using the lowest cost people, it is also ensuring the overall drug development cost is optimal when taking into account productivity, over-sight and expertise. By providing faster access to data, developing more efficient study design approaches and offering complete data reviews across programs that may include many studies over many years, Quanticate plays a key role in supporting its clients."

Prior to Quanticate, Chapple served in leadership positions at Cognizant, ICON Clinical Research and MDS Pharma Services.